MU researcher developing test for swallowing disorder treatments

April 28, 2010

COLUMBIA, Mo. - Muscle degeneration and confinement to a wheelchair are the hallmarks of Lou Gehrig's disease, Parkinson's, muscular dystrophy and other neurodegenerative diseases. One of the silent, and most serious, symptoms of these diseases is losing the ability to swallow. Swallowing impairment, or dysphagia, affects about 500,000 people annually in the U.S., but little is known about the disorder and only a few temporary, behavioral treatments are available. Now, a University of Missouri researcher is developing a test that might help pinpoint the neurological or physiological origins of swallowing disorders, leading to possible life-saving treatments.

"A lot of these diseases attack the limbs, but you don't die because your limbs don't work," said Teresa Lever, assistant professor in department of Communication Science and Disorders at the MU School of Health Professions. "Even though we can give patients feeding tubes with all the nutrients they need, there is no cure for swallowing disorders associated with neurodegenerative diseases, and patients still die early. I am trying to determine what is driving that mortality. If it is swallowing impairment, we need to know how the impairment starts and how we could treat it successfully, which would then improve patients' lifespan and quality of life."

Lever is trying to determine which components of the nervous system that control swallowing are impaired in patients with neurodegenerative diseases. To swallow, the brain must first sense the need to swallow, and then it must activate the right muscles to complete the process. In her study, she is developing an electrophysiological technique for use with mouse models of human neurological diseases that will show which regions of the brain are being used to swallow and which are short-circuiting. After finding which regions of the brain are not working correctly for each disease, treatments, such as stem cell therapy, gene therapy or certain medications, might be used to target those regions. The first disease that she is focusing on is Lou Gehrig's disease, also known as amyotrophic lateral sclerosis or ALS.

"Instead of just treating a behavior, I am trying to determine the source of that behavior," Lever said. "Swallowing is a reflex - you sense the need to swallow and then you have a muscular response. If we find that the sensory component of the swallowing reflex is being impaired along with the neuromuscular component, then many of these neurological diseases may be much more complex than we have been led to believe. It would tell us that our evaluation and treatment of swallowing disorders should not just focus on the muscles and the nerves that stimulate them, but also on the sensory input. It would really create a paradigm shift in the research, especially for ALS which is classified as a motor neuron disease."

Lever recently received a $300,000 grant from the National Institutes of Health for the study. She said that testing will begin in July and expects substantial results in the next two to three years.

Lever's research has been published in the journal Dysphagia.
-end-


University of Missouri-Columbia

Related Amyotrophic Lateral Sclerosis Articles from Brightsurf:

Converting lateral scanning into axial focusing to speed up 3D microscopy
In optical microscopy, high-speed volumetric imaging is limited by either the slow axial scanning rate or aberrations introduced by the z-scanning mechanism.

Ammonium triggers formation of lateral roots
Despite the importance of changes in root architecture to exploit local nutrient patches, mechanisms integrating external nutrient signals into the root developmental program remain poorly understood.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Adjustable lordotic expandable vs static lateral lumbar interbody fusion devices
The objective of this study is to compare the clinical and radiographic outcomes between patients treated with static and expandable interbody spacers with adjustable lordosis for MIS LLIF.

Chirality-assisted lateral momentum transfer for bidirectional enantioselective separation
Chiral nanoparticles which twist the light were theoretically predicted to experience lateral forces perpendicular to light vector but lacks experimental verification.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models
Scientists have delayed the onset of amyotrophic lateral sclerosis (ALS) in laboratory models, leaving them cautiously optimistic that the result, combined with other clinical advances, points to a potential treatment for ALS in humans.

Emerging role of adenosine in brain disorders and amyotrophic lateral sclerosis
The role of adenosine in neurodegeneration and neuroregeneration has led to growing attention on adenosine receptors as potential drug targets in a range of brain disorders, including neuroregenerative therapy and treatment for amyotrophyic lateral sclerosis (ALS).

New clues about the origins of familial forms of Amyotrophic lateral sclerosis
A Brazilian study made important progress in understanding the accumulation of one of the proteins involved in amyotrophic lateral sclerosis (ALS).

Recrutement of a lateral root developmental pathway into root nodule formation of legumes
Peas and other legumes develop spherical or cylindrical structures -- called nodules -- in their roots to establish a mutually beneficial relationship with bacteria that convert atmospheric nitrogen into a useable nutrient for the legume plant.

Read More: Amyotrophic Lateral Sclerosis News and Amyotrophic Lateral Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.